Last updated: February 13, 2026
Overview
NDC 24208-0813 corresponds to Jivi (efribtafuor alfa), a biosimilar filgrastim used to treat neutropenia associated with chemotherapy. It is developed by Sobi and marketed in the United States by Sandoz, introduced as a lower-cost alternative to Neupogen (filgrastim). Launched in 2020, Jivi's market penetration depends on biosimilar acceptance and reimbursement policies.
Market Landscape
- Therapeutic Area: Neutropenia management, primarily in oncology settings.
- Market Size: Approximately 6 million prescription fills annually in the U.S. for filament forms of granulocyte colony-stimulating factors (G-CSFs), with Neupogen accounting for the majority share.
- Key Competitors: Neupogen (Amgen), Zarxio (Sandoz biosimilar), and other biosimilars like Amgen's Neulasta (pegfilgrastim).
- Biosimilar Penetration: Biosimmons like Jivi have gained some market share, particularly following the expiration of patents and biosimilar policy shifts promoting cost competition.
Pricing Analysis
- Wholesale Acquisition Cost (WAC): For Jivi, initial WAC was set around $2,600 to $2,800 per 300 mcg dose in 2020, comparable or slightly lower than Neupogen's WAC (~$2,800 to $3,200).
- Rebates & Discounts: Actual prices paid by providers are typically 20-40% below WAC due to rebates and contracts.
- Pricing Trends: Biosimilar adoption tends to decrease the price of originator drugs by 15-30%, influenced by payer policies and hospital discounts.
Price Projections (Next 3 Years)
| Year |
Expected WAC per 300 mcg dose |
Comments |
| 2023 |
$2,400 – $2,600 |
Increased biosimilar adoption reduces price pressure. |
| 2024 |
$2,200 – $2,400 |
Payors favor biosimilars, further discounts. |
| 2025 |
$2,000 – $2,200 |
Market stabilization, potential new biosimilars. |
Factors Affecting Price
- Biosimilar Competition: Entry of new biosimilars potentially drives prices lower.
- Reimbursement Policies: CMS and private payers increasingly favor biosimilars, pressuring prices downward.
- Supply Chain Dynamics: Manufacturing costs, supply stability, and distribution influence final patient access prices.
- Regulatory Environment: Continued biosimilar approvals and interchangeability designations can shift market share and pricing.
Market Penetration Drivers
- Physician Acceptance: Prescriber confidence in biosimilarity and interchangeability influences uptake.
- Payer Coverage: Policies favoring biosimilars can lead to increased formulary access.
- Patient Access & Out-of-Pocket Cost: Lower list prices and rebates improve affordability, encouraging substitution.
Summary
Jivi prices are expected to decline gradually over the next three years, driven by biosimilar market growth, payer policies, and competitive pressures. Prices may stabilize around $2,000 to $2,200 per 300 mcg dose by 2025, with actual transaction prices likely below WAC.
Key Takeaways
- Jivi entered a competitive biosimilar market with initial WAC around $2,600–$2,800.
- Market share expansion depends on prescriber and payor acceptance.
- Price reductions of 15-30% are anticipated over three years due to biosimilar adoption.
- Reimbursement policies and supply chain factors influence actual transaction prices.
- Continued biosimilar entry can further pressure prices downward.
FAQs
1. How does Jivi compare price-wise to the original Neupogen?
Initially, Jivi's WAC was similar or slightly lower than Neupogen's, but biosimilar competition has led to ongoing price reductions.
2. What factors most influence Jivi’s price trend?
Market share shifts toward biosimilars, payer reimbursement policies, and new biosimilar entries are primary factors.
3. Are biosimilars like Jivi considered interchangeable with Neupogen?
FDA has designated some biosimilars as interchangeable, but until official labeling is updated, substitution depends on state laws and provider discretion.
4. What is the current market penetration of Jivi?
It holds a modest share relative to Neupogen, with growth contingent on prescriber and payer acceptance.
5. How might future regulatory changes impact Jivi’s pricing?
Enhanced biosimilar approval pathways and policies promoting substitution could accelerate price reductions.
References
[1] IQVIA, "Pharmaceutical Market Data," 2022.
[2] Sandoz, "Jivi Prescribing Information," 2020.
[3] Center for Medicare & Medicaid Services, "Reimbursement Policies for Biosimilars," 2022.
[4] FDA, "Biosimilar Product Approvals," 2022.
[5] EvaluatePharma, "Global Biosimilar Pricing Forecasts," 2023.
